EP0362284A1 - Multiple antigen immunoassay - Google Patents

Multiple antigen immunoassay

Info

Publication number
EP0362284A1
EP0362284A1 EP88905482A EP88905482A EP0362284A1 EP 0362284 A1 EP0362284 A1 EP 0362284A1 EP 88905482 A EP88905482 A EP 88905482A EP 88905482 A EP88905482 A EP 88905482A EP 0362284 A1 EP0362284 A1 EP 0362284A1
Authority
EP
European Patent Office
Prior art keywords
antibody
analyte
sample
specific
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP88905482A
Other languages
German (de)
French (fr)
Other versions
EP0362284A4 (en
Inventor
Nigel Genica Pharmaceutical Corp. No. 2 FLEMING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mclean Hospital Corp
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of EP0362284A1 publication Critical patent/EP0362284A1/en
Publication of EP0362284A4 publication Critical patent/EP0362284A4/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms

Definitions

  • the invention relates to a method for the assay of an analyte which may be present in a sample by reacting a sample suspected of containing said analyte with antibodies immobi ⁇ lized to a solid support to form an antibody-antigen complex, followed by titrating the unoccupied antibody with a second labeled antibody which is specific to the first immobilized antibody, followed by detecting the label.
  • immunoassay techni ⁇ ques The detection and quantitation of antigenic substances in biological samples frequently utilize immunoassay techni ⁇ ques. These techniques are based upon the formation of a complex between the antigenic substance being assayed and an antibody or antibodies in which one or the other member of the complex may be detectably labeled. With competitive immunoassay techniques, the antigenic substance in a sample fluid being tested competes with a known quantity of labeled antigen for a limited quantity of antibody binding sites. The amount of labeled antigen bound to the antibody is inversely proportional to the amount of antigen in a sample. By contrast, most, immunometric assays employ a labeled antibody. In such an assay, the amount of labeled antibody associated with the complex is directly proportional to the amount of antigenic substance in a fluid sample.
  • a quantity of unlabeled antibody is bound to a solid support which is insoluble in the fluid being tested.
  • This immobilized antibody is first contacted with the sample being tested so that a binary antigen-antibody complex is formed. After a suitable incubation period, the solid support is washed to remove unbound antigens, then contacted with a solution containing a known quantity of a second antibody. After a second incuba ⁇ tion period, the solid support is then washed a second time to remove the unreacted antibody. A labeled anti-antibody to the second antibody is then added, allowed to incubate for a sufficient amount of time, and the complex then washed.
  • the washed solid support is then tested to detect and quantify the presence of labeled antibody, for example by measuring the emitted radiation of a radioactive label.
  • the amount of labeled antibody detected is compared to that for a negative control sample.
  • This type of assay is frequently referred to as a two-site or sandwich assay, since the antigen has two antibodies bonded to its surface at different locations.
  • sandwich immunoassay has been recognized to be a slow procedure, in part because washing steps are required and lengthy incubation periods are required to reach equilibrium. David, et al. , U.S. Patent No. 4,376,110.
  • simultaneous and reverse assays involve a single incubation step as the antibody bound to the solid support and the labeled antibody are both added to the sample being tested at the same time. After incubation, the solid support is washed to remove unbound analyte and unbound antibody, and the bound antibody-analyte-labeled antibody "sandwich", is detected as with a conventional "forward" sandwich assay.
  • a reverse assay involves the stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support after a suitable incubation.
  • Immunoassays which require only one antigen-specific antibody are preferred.
  • Such an immunoassay was described by Hirano, K. et al.. Anal. Biochem. 154:624-631 (1986) who disclose an assay for tumor-specific alkaline phosphatase using a nitrocellulose filter coated with monoclonal anti ⁇ bodies specific for alkaline phosphatase. The presence of the bound analyte was determined by taking advantage of the enzymatic activity of the bound analyte.
  • this type of immunoassay can only be used for detecting analytes with enzymatic activity which is stable to the conditions of the assay protocol.
  • such assays are not applicable to detection of all enzymes.
  • enzymes such as thiol protease require the addition of reducing agents to stabilize them. Such reducing agents destroy antibodies by cleaving disulfide bonds.
  • a dot-blot assay for the detection and quantitation of the Leishmania glycoconjugate was developed which involves dot-blotting the solubilized protein from parasites onto nitrocellulose, blocking the free protein-binding sites with BLOTTO (5% w/v skim-powdered milk) and detecting the presence of the glycoconjugate with an iodinated monoclonal antibody.
  • BLOTTO 5% w/v skim-powdered milk
  • a second two-site immunoradio etric assay disclosed by Handman for glycoconjugate involved immobilization of monoclonal antibody on nitrocellulose, blocking remaining protein binding sites with BLOTTO, binding with antigen, followed by a second incubation with the same monoclonal antibody, which was radioiodinated.
  • This assay was based on the fact that Leishmania glycoconjugate possesses a large number of epitopes recognized by the monoclonal antibody. This suggests that Leishmania glycoconjugate contains a repetitive polymeric structure. Handman, supra. Thus, this immunoassay is limited to antigens capable of binding two or more identical antibodies.
  • assays which rely on radiodinated monoclonal antibody are relatively expensive because of the high costs of monoclonal antibodies' and the limited shelf lives of most labeled antibodies.
  • Another immunoassay which involves a single antibody comprises immobilization of a monoclonal antibody on nitro ⁇ cellulose, blocking the additional binding sites, and using a labeled antigen to detect the desired antibodies.
  • This method is used to screen hybridoma supernatants and to detect monoclonal antibodies.
  • the antigen is not available in sufficient quantities to allow labeling for use in such an assay. Further, labeling the antigen can result in deleterious alteration of the immuno- ⁇ specificity of the antigen.
  • United States Patent No. 4,279,885 to Reese et__al. describes a solid phase competitive protein binding assay where an antigen or hapten can be assayed.
  • the method involves competition between the analyte and a labeled form thereof for a limited number of receptor or binding sites which are immobilized to a solid support.
  • the assay may be conducted by mixing the components simultaneously or sequentially.
  • the sequential assay involves contacting a solution of an analyte with a support containing immobilized receptors or antibodies, followed by contacting the mixture with a tracer.
  • the tracer may be the analyte, or analog thereof, which contains a label or tag.
  • Competitive assays are generally recognized to be less preferable to non- competitive assays.
  • a sample containing protein to be assayed is mixed with a marker protein in contact with a polystyrene latex.
  • a competition is created between the marker enzyme and the analyte protein for the limited surface binding sites.
  • the inactivation of the enzyme upon binding to the hydrophobic latex surface allows measurement of the bound/free enzyme ratio, and thus, the competing protein concentration.
  • this method is not able to distin ⁇ guish between different proteins, and only gives a measure of the total protein content.
  • an immunoassay which is fast and reliable, and requires the preparation of only one specific antibody. Further, it is desirable to have an immunoassay for a multiplicity of analytes utilizing one specific antibody for each analyte to effect detection.
  • the invention relates to a method for detecting and quantitating an analyte in a sample, which includes
  • step (c) separating said solid support from the incubation mixture obtained in step (b) ;
  • step (e) incubating the mixture formed in step (d) for a time sufficient to allow said titrating antibody to bind to said first antibody;
  • step (f) separating said solid phase support from the incubation mixture obtained in step (e) ;
  • the invention relates as well to an assay for a multi ⁇ plicity of analytes comprising contacting a sample suspected of containing a multiplicity of analytes with a solid support containing different analyte-specific antibodies separately immobilized onto defined areas of the solid phase support, followed by titration and detection with a common titrating antibody.
  • the invention also relates to a kit for the detection of an analyte in a sample comprising a carrier being compart- mentalized to receive in close confinement therein one or more containers wherein
  • a first container contains a solid support containing a first antibody immobilized to said solid support wherein said first antibody is specific to an analyte
  • a second container contains washing buffers
  • a third container contains a titrating antibody specific for the first immobilized antibody.
  • the invention also relates to a kit for the detection of a multiplicity of analytes in a sample which includes a carrier means being compartmentalized to receive in close confinement therein one or more containers wherein
  • a first container contains a solid support contain ⁇ ing a multiplicity of analyte-specific first antibodies separately immobilized to separate defined areas of said solid support;
  • a second container contains washing buffers
  • a third container contains a second titrating antibody specific for each analyte-specific first antibody.
  • the invention offers a convenient, flexible and rapid method to detect and quantify one or more analytes in solution.
  • the invention provides for recycling the solid phase support by elution with a chaotropic salt.
  • the solid phase support may be reused and the antigen recovered from the assay system.
  • FIG. 1 This figure shows the general scheme of the assay, the titration of immobilized IgG not bound to antigen by iodinated IgG-specific antibody, and subsequent recycling of the nitrocellulose disk.
  • Fi ⁇ ure 2 This figure is a plot of the number of disks per tube versus the amount of bound radioactivity.
  • Ficrure 3 This figure shows a comparison of the binding of iodinated sheep anti-rabbit (SAR) antibodies onto differ ⁇ ent types of immobilization matrices, with and without 20% methanol.
  • Ficrure 4 This figure ranks the relative ability of different papers to absorb iodinated SAR with or without 20% methanol.
  • FIG. 6 This figure shows a standard curve for the titration of nitrocellulose-immobilized affinity purified SAR IgG immobilized onto nitrocellulose.
  • FIG. 7 This figure shows a determination of the amount of IgG bound to nitrocellulose disks for a range of different SAR dilutions.
  • Figure 8 This figure depicts a comparison of a 10- minute incubation with an overnight incubation for a series of SAR dilutions.
  • FIG. 9 This figure shows a standard curve for various concentrations of NIRS using SAR-coated nitrocel ⁇ lulose disks, obtained by titration of unbound free antibody sites with iodinated titrating antibody.
  • Figure 10 This figure compares the amount of bound titrating antibody for two different incubation times and varying concentrations of NIRS.
  • FIG. 11 This figure shows the effect of amplifica ⁇ tion of titrating antibody for different concentrations of SAR. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • This invention is directed towards methods of assay by immobilizing a first antibody specific to an analyte on a solid phase support, contacting the sample suspected of containing the analyte with the immobilized antibody, and titrating the unbound antibody with a second labeled antibody which is specific for the first immobilized antibody.
  • solid phase support any support capable of binding antibodies.
  • supports include but are not limited to nitrocellulose, diazocellulose, microtiter plates, glass, polystyrene, polyvinylchloride, polypropylene, polyethylene, dextran, affinity support gels such as Sepharose or agar, starch, and nylon.
  • Preferred supports are nitrocellulose and diazocellulose.
  • antibody refers both to monoclonal antibodies which have a substantially homogeneous population and to polyclonal antibodies which have heterogeneous populations. Both the first and second antibodies may be monoclonal or polyclonal. Polyclonal antibodies are derived from the antisera of animals immunized with the analyte. Monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497 (1975). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
  • antibody is meant as well to include both intact molecules as well as fragments thereof, such as, for example. Fab and F(ab') 2 , which are capable of binding antigen.
  • analyte is intended any molecule with an antigenic site capable of binding to an antibody. Such analytes may include but are not limited to proteins, drugs, viruses, cells, haptens, subcellular particles, carbo ⁇ hydrates, hormones, vitamins, metabolites and their binding materials.
  • the first analyte-specific antibody is a polyclonal antibody derived from an animal immunized with the analyte.
  • the second titrating antibody may be heterologous polyclonal antibodies which are specific against the immunoglobulins comprising the first antibody.
  • the second antibody may be obtained by isolating the antibodies from a second animal species which has been immunized with antisera from the same species of animal used to prepare the first antibody.
  • a first IgG monoclonal antibody which is specific to the analyte to be assayed is used.
  • the second titrating antibody comprises a detectably labeled anti-IgG polyclonal antibody specific to the first antibody.
  • a first IgG polyclonal antibody which is specific to the analyte to be assayed, is used.
  • the second titrating antibody comprises a detectably labeled anti-IgG monoclonal antibody specific to the first antibody.
  • a number of different analyte-specific antibodies derived from the same animal species may be separately immobilized on defined areas of a solid support which is attached to a dip stick.
  • the dip stick may be incubated with a sample to assay for many different analytes simultaneously.
  • the unoccupied antibody sites on each defined area can then be titrated with common titrating antibodies which are specific for each antigen- specific antibody.
  • each analyte-specific antibody may be of the IgG class.
  • the common titrating antibodies will then be anti-IgG antibodies.
  • the term "common titrating antibodies" is used in the plural, although it will be understood that only one class of antibodies is intended.
  • the amount of bound analyte is determined indirectly by measuring the amount of label associated with the second antibody which binds to the unoccupied first antibody.
  • the amount of analyte present in a sample is inversely propor ⁇ tional to the amount of label present.
  • labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include, but are not limited to, enzymes, radioisotopes, dyes, fluorescent compounds, che iluminescent compounds, bioluminescent compounds and metal chelates. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain the same by the use of routine experimentation. Furthermore, the binding of these labels to the antibodies can be accomplished using standard techniques commonly known to those of ordinary skill in the art.
  • titrating antibody of the present invention can be detectably labeled is by linking the same to an enzyme.
  • This enzyme when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric, fluorometric or visual means.
  • enzymes which can be used to detectably label the antibody of the present invention include malate dehydrogenase, staphylococcal nuclease, delta- V-steroid isomerase, yeast alcohol dehydrogenase, alpha- glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.
  • Avidin-biotin binding may be used to facilitate the enzyme labeling.
  • the titrating antibody of the present invention can also be labeled with a radioactive isotope which can then be determined by such means as the use of a gamma counter or a scintillation counter.
  • a radioactive isotope which are particularly useful for the purpose of the present invention are: 3 H, 125 I, 131 I, 3 P. 35 S/ 14 Cf 51 Cr/ 36 clf 57 C ⁇ / 58 C ⁇ / 59 Fe and
  • fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • the titrating antibody of the invention can also be detectably labeled using fluorescent emitting metals such as 152 Eu, or others of the lanthanide series. These metals can be attached to the antibody molecule using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA) .
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • the titrating antibody of the present invention also can be detectably labeled by coupling it to a chemiluminescent compound.
  • the presence of the chemiluminescent-tagged titrating antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemi- luminescent labeling compounds are luminol, isoluminol, thero atic acridinium ester, i idazole, acridinium salt and oxalate ester.
  • Bioluminescent compound may be used to label the titrating antibody of the present invention.
  • Biolumi- nescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a biolumi ⁇ nescent antibody is determined by detecting the presence of luminescence.
  • Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
  • Another technique which may also result in greater sensitivity when used in conjunction with the present invention consists of coupling the titrating antibody of the present invention to low molecular weight haptens.
  • the haptens can then be specifically detected by means of a second reaction.
  • the sensitivity of the assay may be increased by use of amplification strategies including substrate cycling and enzyme channeling as taught by Mosbach, supra. incorporated by reference herein.
  • the analyte which is detected by this assay may be present in a sample solution.
  • the sample is a biological sample such as, for example, saliva, cerebrospinal fluid, blood, serum, urine, water, food and the like.
  • the invention is not limited to assays using only these samples, it being possible for one of ordinary skill in the art to determine suitable conditions which allow the use of other samples.
  • various chemicals and drugs are also capable of being antigens, and thus may be suitable assayed in water, food, or other samples by the methods of this invention.
  • the process comprises: a) contacting a sample suspected of containing a multiplicity of analytes with a solid support on which different analyte-specific first antibodies have been separately immobilized to separately defined areas of said solid support: b) incubating said sample with said support for a sufficient amount of time to allow the analytes present in the sample to bind to said first antibodies; c) separating the solid phase support from the incubation mixture obtained in step b) ; d) -contacting said solid support with a detectably labeled titrating antibodies which are specific for said first antibodies; e) incubating the mixture formed in step d) for a time sufficient to allow said titrating antibodies to bind to said first antibodies; f) separating said solid, phase support from the incubation mixture obtained in step e) ; and. g) detecting the analyte in
  • the specific concentrations of label and analyte, the temperature and time of incubation, as well as other assay conditions may be varied, depending on various factors including the concentration of antigen in the sample, the nature of the sample, and the like. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
  • the eluted titrating antibody may be separated from the eluted analyte accoding to means known in the art and also recycled for reuse in the assay. The eluted analyte may further be recovered.
  • Detection of the labeled antibody may be accomplished by a scintillation counter, for example, if the label is a radioactive gamma emitter, or by a fluorometer, for example, if the label is a fluorescent material.
  • the detection can be accomplished by colori- etric methods which employ a substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with standards.
  • the solid phase immunosorbent may be recycled by elution of the antigen and the titrating antibody with a chaotropic salt such as MgCl 2 .
  • a chaotropic salt such as MgCl 2
  • the invention is not limited to the use of MgCl 2 , it being possible for one of ordinary skill in the art to determine other chaotropic salts which may be used to recycle the solid phase immunosorbent, without undue experimentation.
  • the eluted titrating antibody may be separated from the eluted analyte according to means known in the art and may also then be recovered for re-use. The eluted analyte may further be recovered.
  • the assay of the present invention is ideally suited for the preparation of a kit.
  • a kit may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the immunoassay.
  • container means such as vials, tubes and the like
  • each of said container means comprising the separate elements of the immunoassay.
  • container means containing the first antibody immobil ⁇ ized on a solid phase support
  • Further container means may contain standard solutions comprising serial dilutions of analytes to be detected.
  • the standard solutions of these analytes may be used to prepare a standard curve with the concentration of the analyte plotted on the abscissa and the detection signal on the ordinate.
  • the results obtained from a sample contain ⁇ ing an analyte may be interpolated from such a plot to give the concentration of the analyte.
  • a container means containing a dipstick which comprises a multiplicity of different analyte-specific antibodies separately immobilized to separate defined areas of the solid phase support.
  • Further container means may contain a common titrating antibody which is specific for each analyte- specific antibody.
  • Further container means may contain standard solutions of analytes to be detected. The standard solutions of these analytes may be used to provide a standard reference dipstick for comparison with the sample dipstick.
  • a simple antibody-antigen system illustrates the protocol used for the assay for one antigen by isotopic detection.
  • Sheep anti-rabbit serum (SAR) was induced by sheep by standard procedures and heat inactivated at 56 ⁇ C for 30 minutes.
  • Rabbit IgG was purchased from Sigma (St. Louis, MO) .
  • Iodination was achieved using iodo-beads (Pierce Chemical Company, Rockford, IL) using carrier-free sodium iodide-I 125 (Dupont New England Nuclear, Boston, MA) . All other chemicals were reagent grade and were purchased from either Sigma Chemical Corporation (St. Louis, MO) or Fisher (Medford, MA) .
  • Nitrocellulose paper (Millipore filter type HAHY 000-10, 0.45 uM pore size, Millipore Corporation, Bedford, MA) was used unless stated otherwise.
  • the other papers tested include: Zeta Probe blotting membrane (cationized nylon, BioRad, Richmond, CA) , mixed cellulose acetate and nitrate paper (GSWP 013-00, 0.22 uM pore size) and Millipore MF filters (HAWGO4750, 0.45 uM pore size, Millipore Corporation, Bedford, MA) , high binding capacity S&S Nytran (positively charged hydrophilic nylon-66, pore sizes 0.2 uM and 0.45 uM) ,• S&S pure 100% hydrophilic nitrocellulose in different pore sizes (no cellulose acetate added, PH70, 0.025 uM pore size and BA83, pore size 0.2 uM, and BA85, pore size 0.45 uM, Schleicher and Schuell, Keene, NH)
  • Blocking buffers included 10% (v/v) bovine serum, 3% BSA, or 5% Carnation nonfat milk.
  • the antigen (rabbit IgG) was then added (50-300 ul) and incubated for 30-60 minutes, as indicated in the following Examples. After washing three times, iodinated non-immune rabbit serum (NIRS-I 125 ) was added (50-300 ul) for the time stated (30 minutes minimum) . After a second wash, the samples were counted for gamma radiation on a 40% efficient Packard Auto-Gamma Scintillation Spectrophotometer Model 5220.
  • the efficiency of IgG immobilization on nitrocellulose disks was determined as follows. Serial dilutions of SAR were incubated with a nitrocellulose disk. The nitrocellu ⁇ lose filter were then washed and titrated with iodinated antisera. A plot of the amount of bound IgG, as represented by the amount of radioactivity, appears schematically in the inset to Figure 2.
  • the competition between IgG and the larger proportion of other serum proteins for protein binding sites on nitrocellulose results in the affinity displacement (A) of IgG at high serum concentrations. As the antiserum concentration diminishes, the amount of immobilized IgG increases until the inflection point (X) is reached, where all the sample protein is absorbed equally. Diminishing concentrations of IgG beyond the inflection point are then reflected by diminishing counts of titrating antibody (B) .
  • FIG. 2 shows the relationship between the number of nitrocellulose disks and the amount of bound radioactivity.
  • 500 uL of sheep anti-rabbit serum was incubated for 10 minutes with 1-10 disks as shown in Figure 2, washed with Tris buffer, blocked with 1 ml of 10% bovine serum blocker for 20 minutes, washed, titrated with 1 ml of NIRS-I 125 for 60 minutes, washed, and the radioactivity bound to the disk determined.
  • the number of binding sites was no longer limiting for that concentration of sample. This illustrates that it is advantageous to use dilute sera for coating the matrix.
  • purified IgG may be used to achieve high coating densities.
  • Nitrocellulose disks in this experiment were recycled four times. Nitrocellulose disks containing immobilized sheep anti-rabbit IgG and titrating antibody NIRS-I 125 were eluted with 2.5 M MgCl 2 and the loss of antibody during the elution cycle determined. Four elutions with MgCl resulted in a 20% loss of absorbed antibody (as determined by iodinated sheep anti-rabbit serum) as. shown in Figure 5.
  • the disks were incubated with 150 uL of iodinated NIRS-antigen for 60 minutes, followed by washing in milk buffer, and counting the radioactivity remaining on the disk. Background counts were determined using the counts adhering after elution of the iodinated antigen. All data as shown in Figure 5 is normali ⁇ zed as a percentage of the starting value. During regenera ⁇ tion cycles, nonspecific binding increased gradually, which indicates the absorption of label onto sites vacated by the trl ⁇ cker protein or the sheep anti-rabbit serum.
  • the amount of IgG necessary to give a readable signal was .determined.
  • Five ul aliquots of serial dilutions of SAR were spotted onto disks of nitrocellulose and dried. They were blocked for 30 minutes in 2 ml of 5% nonfat milk, washed in Tris-EDTA, and incubated with 150 ul of iodinated NIRS in 3% BSA for 60 minutes. Following thorough washing, the radioactivity bound to the disks was determined. As can be seen in Figure 6, the lowest detect ⁇ able amount of bound IgG under these conditions was approxi ⁇ mately 25 ng.
  • a parallel series of experiments were con ⁇ ducted by amplifying the detection signal with iodinated SAR. Again, the lowest detection limit was. about 25 ng.
  • the amount of IgG bound to the disks after brief incubation with a range of serum dilutions is depicted in Figure 7. 100% efficient absorption was achieved at a titre of approximately 1:500. At lower dilutions, decreasing amounts of sample IgG were absorbed onto the matrix. The capacity of the nitrocellulose is approximately 80 ug/cm 2 . The area of the disk used was about 1 cm 2 . Thus, the amount of specific IgG is far short of saturating the disk. About 50% absorption of total sample IgG was achieved by using 1:128 dilution of serum.
  • the relationship between the time of incubation of the titrating labeled antibody (60 or 140 minutes) and the amount of bound label for various serial dilutions of NIRS appears Figure 10.
  • the disks were coated with SAR at a 1:4 dilution (100 ul for 20 minutes) , blocked for 20 minutes in 1 ml of 5% nonfat milk buffer, and incubated with 200 ul of serial dilutions of NIRS serum overnight at 4*C. After thorough washing, the free sites were titrated with 100 ul of iodinated NIRS for the time specified. After washing, the radioactivity bound to the disk was determined.
  • the 140 minute incubation did increase the amount of bound label and the amplitude of the signal, although the error bars were greater. This indicated that there was an increased amount of nonspecific binding with longer incuba ⁇ tion times.
  • the amplification was greatest at low concentra ⁇ tions of sample NIRS, where the number of free IgG binding sites was greatest.
  • the titrating antibody may have a greater affinity for the immobilized IgG than the sample antigen.
  • Antigen-free IgG molecules were incubated with iodinated NIRS followed by binding the remaining unbound IgG molecules with an excess of unlabeled anti-IgG molecules to provide a carpet for the subsequent binding of a second labeled anti-IgG molecule.
  • Amplification occurs as a result of the ability of each immobilized primary antibody to bind to more than one labeled IgG molecule.
  • This second layer of molecules allows a higher binding of a second labeled titrating antibody by virtue of mass action. Further, there is a higher probability of collision between the titrating IgG molecule and the "carpet" target IgG molecules than collision with primary immobilized antibody due to their number.

Abstract

Analyse d'un ou de plusieurs analytes consistant à mettre en contact un échantillon, dont on suppose qu'il contient un ou plusieurs analytes, avec une phase solide contenant un ou plusieurs anticorps spécifiques d'antigènes différents immobilisés séparément dans des zones définies sur la phase solide, suivi par la détection indirecte de la présence d'antigène lié par titrage des anticorps immobilisés non liés, au moyen d'un anticorps de titrage, spécifique au premier anticorps. Cette analyse permet la détection simultanée d'une multiplicité d'antigènes par une seule analyse.Analysis of one or more analytes consisting in bringing a sample, which is supposed to contain one or more analytes, into contact with a solid phase containing one or more antibodies specific for different antigens immobilized separately in defined zones on the solid phase, followed by indirect detection of the presence of bound antigen by titration of unbound immobilized antibodies, using a titration antibody, specific to the first antibody. This analysis allows the simultaneous detection of a multiplicity of antigens by a single analysis.

Description

MULTIPLE ANTIGEN IMMUNOASSAY
Field of the Invention
The invention relates to a method for the assay of an analyte which may be present in a sample by reacting a sample suspected of containing said analyte with antibodies immobi¬ lized to a solid support to form an antibody-antigen complex, followed by titrating the unoccupied antibody with a second labeled antibody which is specific to the first immobilized antibody, followed by detecting the label.
BACKGROUND OF THE INVENTION
The detection and quantitation of antigenic substances in biological samples frequently utilize immunoassay techni¬ ques. These techniques are based upon the formation of a complex between the antigenic substance being assayed and an antibody or antibodies in which one or the other member of the complex may be detectably labeled. With competitive immunoassay techniques, the antigenic substance in a sample fluid being tested competes with a known quantity of labeled antigen for a limited quantity of antibody binding sites. The amount of labeled antigen bound to the antibody is inversely proportional to the amount of antigen in a sample. By contrast, most, immunometric assays employ a labeled antibody. In such an assay, the amount of labeled antibody associated with the complex is directly proportional to the amount of antigenic substance in a fluid sample.
In sandwich immunometric assays, a quantity of unlabeled antibody is bound to a solid support which is insoluble in the fluid being tested. This immobilized antibody is first contacted with the sample being tested so that a binary antigen-antibody complex is formed. After a suitable incubation period, the solid support is washed to remove unbound antigens, then contacted with a solution containing a known quantity of a second antibody. After a second incuba¬ tion period, the solid support is then washed a second time to remove the unreacted antibody. A labeled anti-antibody to the second antibody is then added, allowed to incubate for a sufficient amount of time, and the complex then washed. The washed solid support is then tested to detect and quantify the presence of labeled antibody, for example by measuring the emitted radiation of a radioactive label. The amount of labeled antibody detected is compared to that for a negative control sample. This type of assay is frequently referred to as a two-site or sandwich assay, since the antigen has two antibodies bonded to its surface at different locations. Despite their great utility, sandwich immunoassay has been recognized to be a slow procedure, in part because washing steps are required and lengthy incubation periods are required to reach equilibrium. David, et al. , U.S. Patent No. 4,376,110.
To eliminate at least one of the washing steps associa¬ ted with this procedure, so-called simultaneous and reverse assays have been developed. A simultaneous assay involves a single incubation step as the antibody bound to the solid support and the labeled antibody are both added to the sample being tested at the same time. After incubation, the solid support is washed to remove unbound analyte and unbound antibody, and the bound antibody-analyte-labeled antibody "sandwich", is detected as with a conventional "forward" sandwich assay. A reverse assay involves the stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support after a suitable incubation. After a second incubation, the solid phase is washed in conventional fashion and the amount of labeled complex is detected as before. United States Patent No. 4,098,876 to Piasio, et al. However, all of these methods suffer from the requirement for two antigen-specific antibodies which are able to recognize separate and distinct epitopes on an antigen. This is a critical limitation which makes the application of such immunoassays impractical for small antigens.
Immunoassays which require only one antigen-specific antibody are preferred. Such an immunoassay was described by Hirano, K. et al.. Anal. Biochem. 154:624-631 (1986) who disclose an assay for tumor-specific alkaline phosphatase using a nitrocellulose filter coated with monoclonal anti¬ bodies specific for alkaline phosphatase. The presence of the bound analyte was determined by taking advantage of the enzymatic activity of the bound analyte. Thus, this type of immunoassay can only be used for detecting analytes with enzymatic activity which is stable to the conditions of the assay protocol. In addition, such assays are not applicable to detection of all enzymes. For example, enzymes such as thiol protease require the addition of reducing agents to stabilize them. Such reducing agents destroy antibodies by cleaving disulfide bonds.
A dot-blot assay for the detection and quantitation of the Leishmania glycoconjugate was developed which involves dot-blotting the solubilized protein from parasites onto nitrocellulose, blocking the free protein-binding sites with BLOTTO (5% w/v skim-powdered milk) and detecting the presence of the glycoconjugate with an iodinated monoclonal antibody. Handman, E. et al.. J. Immunol. Meth. __3.:113-123 (1985). A second two-site immunoradio etric assay disclosed by Handman for glycoconjugate involved immobilization of monoclonal antibody on nitrocellulose, blocking remaining protein binding sites with BLOTTO, binding with antigen, followed by a second incubation with the same monoclonal antibody, which was radioiodinated. This assay was based on the fact that Leishmania glycoconjugate possesses a large number of epitopes recognized by the monoclonal antibody. This suggests that Leishmania glycoconjugate contains a repetitive polymeric structure. Handman, supra. Thus, this immunoassay is limited to antigens capable of binding two or more identical antibodies. In addition, assays which rely on radiodinated monoclonal antibody are relatively expensive because of the high costs of monoclonal antibodies' and the limited shelf lives of most labeled antibodies.
Another immunoassay which involves a single antibody comprises immobilization of a monoclonal antibody on nitro¬ cellulose, blocking the additional binding sites, and using a labeled antigen to detect the desired antibodies. Suresh, M.R. et al.. Anal. Biochem. 151:192-195 (1985). This method is used to screen hybridoma supernatants and to detect monoclonal antibodies. However, in many instances, the antigen is not available in sufficient quantities to allow labeling for use in such an assay. Further, labeling the antigen can result in deleterious alteration of the immuno- ~specificity of the antigen.
United States Patent No. 4,279,885 to Reese et__al. , describes a solid phase competitive protein binding assay where an antigen or hapten can be assayed. The method involves competition between the analyte and a labeled form thereof for a limited number of receptor or binding sites which are immobilized to a solid support. The assay may be conducted by mixing the components simultaneously or sequentially. The sequential assay involves contacting a solution of an analyte with a support containing immobilized receptors or antibodies, followed by contacting the mixture with a tracer. The tracer may be the analyte, or analog thereof, which contains a label or tag. Competitive assays are generally recognized to be less preferable to non- competitive assays.
It is also possible to have assays which do not utilize antibodies at all. For example, a sample containing protein to be assayed is mixed with a marker protein in contact with a polystyrene latex. A competition is created between the marker enzyme and the analyte protein for the limited surface binding sites. The inactivation of the enzyme upon binding to the hydrophobic latex surface allows measurement of the bound/free enzyme ratio, and thus, the competing protein concentration. However, this method is not able to distin¬ guish between different proteins, and only gives a measure of the total protein content. Sandwick, et al. , Anal. Biochem. 7:210-216 (1985).
Further improvements to immunoassay techniques involve the use of amplification strategies to increase the detection limit. These strategies include substrate cycling and enzyme channeling. Mosbach, K. , Ann. N. Y. Acad. Sci. 434:239-248 (1984) . However, neither system has been widely adopted.
Thus, it would be desirable to have an immunoassay which is fast and reliable, and requires the preparation of only one specific antibody. Further, it is desirable to have an immunoassay for a multiplicity of analytes utilizing one specific antibody for each analyte to effect detection.
srmτ--ry of the Invention
The invention relates to a method for detecting and quantitating an analyte in a sample, which includes
(a) contacting a sample suspected of containing the analyte with a solid phase support onto which an analyte- specific first antibody has been immobilized;
(b) incubating said sample with said support for a sufficient amount of time to allow the analyte present in the sample to bind to said first antibody;
(c) separating said solid support from the incubation mixture obtained in step (b) ;
.. (d) contacting said solid phase support with a detect- ably labeled titrating antibody which is specific for said first antibody;
(e) incubating the mixture formed in step (d) for a time sufficient to allow said titrating antibody to bind to said first antibody;
(f) separating said solid phase support from the incubation mixture obtained in step (e) ; and
(g) detecting the analyte in the sample by measuring the amount of bound labeled antibody.
The invention relates as well to an assay for a multi¬ plicity of analytes comprising contacting a sample suspected of containing a multiplicity of analytes with a solid support containing different analyte-specific antibodies separately immobilized onto defined areas of the solid phase support, followed by titration and detection with a common titrating antibody.
The invention also relates to a kit for the detection of an analyte in a sample comprising a carrier being compart- mentalized to receive in close confinement therein one or more containers wherein
(a) a first container contains a solid support containing a first antibody immobilized to said solid support wherein said first antibody is specific to an analyte;
(b) a second container contains washing buffers; and
(c) a third container contains a titrating antibody specific for the first immobilized antibody.
The invention also relates to a kit for the detection of a multiplicity of analytes in a sample which includes a carrier means being compartmentalized to receive in close confinement therein one or more containers wherein
(a) a first container contains a solid support contain¬ ing a multiplicity of analyte-specific first antibodies separately immobilized to separate defined areas of said solid support;
(b) a second container contains washing buffers; and
(c) a third container contains a second titrating antibody specific for each analyte-specific first antibody.
The invention offers a convenient, flexible and rapid method to detect and quantify one or more analytes in solution. In addition, the invention provides for recycling the solid phase support by elution with a chaotropic salt. Thus, the solid phase support may be reused and the antigen recovered from the assay system.
DESCRIPTION OF THE FIGURES
Figure 1. This figure shows the general scheme of the assay, the titration of immobilized IgG not bound to antigen by iodinated IgG-specific antibody, and subsequent recycling of the nitrocellulose disk. Fiσure 2. This figure is a plot of the number of disks per tube versus the amount of bound radioactivity.
Ficrure 3. This figure shows a comparison of the binding of iodinated sheep anti-rabbit (SAR) antibodies onto differ¬ ent types of immobilization matrices, with and without 20% methanol.
Ficrure 4. This figure ranks the relative ability of different papers to absorb iodinated SAR with or without 20% methanol.
Fiσure 5. This figure shows the effect of recycling antibody coated disks on the amount of residual radioactivity associated with the absorbed antibody.
Figure 6. This figure shows a standard curve for the titration of nitrocellulose-immobilized affinity purified SAR IgG immobilized onto nitrocellulose.
Figure 7. This figure shows a determination of the amount of IgG bound to nitrocellulose disks for a range of different SAR dilutions.
Figure 8. This figure depicts a comparison of a 10- minute incubation with an overnight incubation for a series of SAR dilutions.
Figure 9. This figure shows a standard curve for various concentrations of NIRS using SAR-coated nitrocel¬ lulose disks, obtained by titration of unbound free antibody sites with iodinated titrating antibody.
Figure 10. This figure compares the amount of bound titrating antibody for two different incubation times and varying concentrations of NIRS.
Figure 11. This figure shows the effect of amplifica¬ tion of titrating antibody for different concentrations of SAR. DESCRIPTION OF THE PREFERRED EMBODIMENTS
This invention is directed towards methods of assay by immobilizing a first antibody specific to an analyte on a solid phase support, contacting the sample suspected of containing the analyte with the immobilized antibody, and titrating the unbound antibody with a second labeled antibody which is specific for the first immobilized antibody.
By "solid phase support" is intended any support capable of binding antibodies. Such supports include but are not limited to nitrocellulose, diazocellulose, microtiter plates, glass, polystyrene, polyvinylchloride, polypropylene, polyethylene, dextran, affinity support gels such as Sepharose or agar, starch, and nylon. Preferred supports are nitrocellulose and diazocellulose. Those skilled in the art will note that many other suitable carriers for binding monoclonal antibody exist, or will be able to ascertain the same by use of routine experimentation.
The term "antibody" refers both to monoclonal antibodies which have a substantially homogeneous population and to polyclonal antibodies which have heterogeneous populations. Both the first and second antibodies may be monoclonal or polyclonal. Polyclonal antibodies are derived from the antisera of animals immunized with the analyte. Monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497 (1975). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
The . term "antibody" is meant as well to include both intact molecules as well as fragments thereof, such as, for example. Fab and F(ab')2, which are capable of binding antigen. By the term "analyte" is intended any molecule with an antigenic site capable of binding to an antibody. Such analytes may include but are not limited to proteins, drugs, viruses, cells, haptens, subcellular particles, carbo¬ hydrates, hormones, vitamins, metabolites and their binding materials.
In one embodiment, the first analyte-specific antibody is a polyclonal antibody derived from an animal immunized with the analyte. The second titrating antibody may be heterologous polyclonal antibodies which are specific against the immunoglobulins comprising the first antibody. The second antibody may be obtained by isolating the antibodies from a second animal species which has been immunized with antisera from the same species of animal used to prepare the first antibody.
In another embodiment, a first IgG monoclonal antibody which is specific to the analyte to be assayed is used. The second titrating antibody comprises a detectably labeled anti-IgG polyclonal antibody specific to the first antibody.
In still another embodiment, a first IgG polyclonal antibody, which is specific to the analyte to be assayed, is used. The second titrating antibody comprises a detectably labeled anti-IgG monoclonal antibody specific to the first antibody.
In a preferred embodiment, a number of different analyte-specific antibodies derived from the same animal species may be separately immobilized on defined areas of a solid support which is attached to a dip stick. Thus, the dip stick may be incubated with a sample to assay for many different analytes simultaneously. The unoccupied antibody sites on each defined area can then be titrated with common titrating antibodies which are specific for each antigen- specific antibody. For instance, each analyte-specific antibody may be of the IgG class. The common titrating antibodies will then be anti-IgG antibodies. As used herein, the term "common titrating antibodies" is used in the plural, although it will be understood that only one class of antibodies is intended. This aspect of the invention provides for the simultaneous detection and quantitation of a multiplicity of antigens by a universal labeling method.
The amount of bound analyte is determined indirectly by measuring the amount of label associated with the second antibody which binds to the unoccupied first antibody. The amount of analyte present in a sample is inversely propor¬ tional to the amount of label present. There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include, but are not limited to, enzymes, radioisotopes, dyes, fluorescent compounds, che iluminescent compounds, bioluminescent compounds and metal chelates. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain the same by the use of routine experimentation. Furthermore, the binding of these labels to the antibodies can be accomplished using standard techniques commonly known to those of ordinary skill in the art.
One of the ways in which the titrating antibody of the present invention can be detectably labeled is by linking the same to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric, fluorometric or visual means. Examples of enzymes which can be used to detectably label the antibody of the present invention include malate dehydrogenase, staphylococcal nuclease, delta- V-steroid isomerase, yeast alcohol dehydrogenase, alpha- glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase. Avidin-biotin binding may be used to facilitate the enzyme labeling.
The titrating antibody of the present invention can also be labeled with a radioactive isotope which can then be determined by such means as the use of a gamma counter or a scintillation counter. Isotopes which are particularly useful for the purpose of the present invention are: 3H, 125I, 131I, 3 P. 35S/ 14Cf 51Cr/ 36clf 57Cθ/ 58Cθ/ 59Fe and
75Se.
It is also possible to label the titrating antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to the fluorescence of the dye. Among the most commonly used fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
The titrating antibody of the invention can also be detectably labeled using fluorescent emitting metals such as 152Eu, or others of the lanthanide series. These metals can be attached to the antibody molecule using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA) .
The titrating antibody of the present invention also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged titrating antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemi- luminescent labeling compounds are luminol, isoluminol, thero atic acridinium ester, i idazole, acridinium salt and oxalate ester.
Likewise, a bioluminescent compound may be used to label the titrating antibody of the present invention. Biolumi- nescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a biolumi¬ nescent antibody is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
Another technique which may also result in greater sensitivity when used in conjunction with the present invention consists of coupling the titrating antibody of the present invention to low molecular weight haptens. The haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin (reacting with avidin) or dinitrophenyl, pyridoxal and fluoresca ine (reacting with specific anti- hapten antibodies) in this manner.
In addition, the sensitivity of the assay may be increased by use of amplification strategies including substrate cycling and enzyme channeling as taught by Mosbach, supra. incorporated by reference herein.
For the purposes of the present invention, the analyte which is detected by this assay may be present in a sample solution. Normally, the sample is a biological sample such as, for example, saliva, cerebrospinal fluid, blood, serum, urine, water, food and the like. However, the invention is not limited to assays using only these samples, it being possible for one of ordinary skill in the art to determine suitable conditions which allow the use of other samples. For instance, various chemicals and drugs are also capable of being antigens, and thus may be suitable assayed in water, food, or other samples by the methods of this invention.
In carrying out the titrating immunoassay of the present invention on a sample containing a multiplicity of analytes, the process comprises: a) contacting a sample suspected of containing a multiplicity of analytes with a solid support on which different analyte-specific first antibodies have been separately immobilized to separately defined areas of said solid support: b) incubating said sample with said support for a sufficient amount of time to allow the analytes present in the sample to bind to said first antibodies; c) separating the solid phase support from the incubation mixture obtained in step b) ; d) -contacting said solid support with a detectably labeled titrating antibodies which are specific for said first antibodies; e) incubating the mixture formed in step d) for a time sufficient to allow said titrating antibodies to bind to said first antibodies; f) separating said solid, phase support from the incubation mixture obtained in step e) ; and. g) detecting the analyte in the sample by measuring the amount of bound labeled titrating antibodies to each separately defined area.
Of course, the specific concentrations of label and analyte, the temperature and time of incubation, as well as other assay conditions may be varied, depending on various factors including the concentration of antigen in the sample, the nature of the sample, and the like. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation. In addition, the eluted titrating antibody may be separated from the eluted analyte accoding to means known in the art and also recycled for reuse in the assay. The eluted analyte may further be recovered.
Detection of the labeled antibody may be accomplished by a scintillation counter, for example, if the label is a radioactive gamma emitter, or by a fluorometer, for example, if the label is a fluorescent material. In the case of an enzyme label, the detection can be accomplished by colori- etric methods which employ a substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with standards.
Other such steps as washing, stirring, shaking, filter¬ ing and the like may of course be added to the assays as is customary or necessary for the particular situation.
The solid phase immunosorbent may be recycled by elution of the antigen and the titrating antibody with a chaotropic salt such as MgCl2. However, the invention is not limited to the use of MgCl2, it being possible for one of ordinary skill in the art to determine other chaotropic salts which may be used to recycle the solid phase immunosorbent, without undue experimentation. In addition, the eluted titrating antibody may be separated from the eluted analyte according to means known in the art and may also then be recovered for re-use. The eluted analyte may further be recovered.
The assay of the present invention is ideally suited for the preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the immunoassay. For example, there may be a container means containing the first antibody immobil¬ ized on a solid phase support, and further container means containing detectably labeled titrating antibodies, in solution. Further container means may contain standard solutions comprising serial dilutions of analytes to be detected. The standard solutions of these analytes may be used to prepare a standard curve with the concentration of the analyte plotted on the abscissa and the detection signal on the ordinate. The results obtained from a sample contain¬ ing an analyte may be interpolated from such a plot to give the concentration of the analyte.
In another embodiment of the kit, there may be a container means containing a dipstick which comprises a multiplicity of different analyte-specific antibodies separately immobilized to separate defined areas of the solid phase support. Further container means may contain a common titrating antibody which is specific for each analyte- specific antibody. Further container means may contain standard solutions of analytes to be detected. The standard solutions of these analytes may be used to provide a standard reference dipstick for comparison with the sample dipstick.
The various aspects of the invention are further described in the following examples. These examples are not intended to limit the invention in any manner.
EXAMPLES
EXAMPLE 1 General Procedure For the Immunoassay
In the examples that follow, a simple antibody-antigen system illustrates the protocol used for the assay for one antigen by isotopic detection. Sheep anti-rabbit serum (SAR) was induced by sheep by standard procedures and heat inactivated at 56βC for 30 minutes. Rabbit IgG was purchased from Sigma (St. Louis, MO) . Iodination was achieved using iodo-beads (Pierce Chemical Company, Rockford, IL) using carrier-free sodium iodide-I125 (Dupont New England Nuclear, Boston, MA) . All other chemicals were reagent grade and were purchased from either Sigma Chemical Corporation (St. Louis, MO) or Fisher (Medford, MA) .
Nitrocellulose paper (Millipore filter type HAHY 000-10, 0.45 uM pore size, Millipore Corporation, Bedford, MA) was used unless stated otherwise. The other papers tested include: Zeta Probe blotting membrane (cationized nylon, BioRad, Richmond, CA) , mixed cellulose acetate and nitrate paper (GSWP 013-00, 0.22 uM pore size) and Millipore MF filters (HAWGO4750, 0.45 uM pore size, Millipore Corporation, Bedford, MA) , high binding capacity S&S Nytran (positively charged hydrophilic nylon-66, pore sizes 0.2 uM and 0.45 uM) ,• S&S pure 100% hydrophilic nitrocellulose in different pore sizes (no cellulose acetate added, PH70, 0.025 uM pore size and BA83, pore size 0.2 uM, and BA85, pore size 0.45 uM, Schleicher and Schuell, Keene, NH) , Hydrophilic Hybond-C 87 mm nitrocellulose and Hybond-N 132 mm nylon membranes (Amersham Corporation, Arlington Heights, IL) .
Seven millimeter diameter disks of nitrocellulose (Millipore HA 0.45 uM pore, unless stated otherwise) were made using a standard office hole puncher and transferred by needle to a 15 x 75 millimeter polystyrene tube. Volumes between 50-300 ul of diluted antisera (SAR) were incubated with the disks at room temperature for 10 minutes. After washing in Tris-EDTA-azide, the samples were incubated in 1-2 ml of blocker. All titration and wash buffers utilized a base buffer of 50 mM Tris, 5 mM EDTA, 0.01% sodium azide at pH 7.4. Blocking buffers included 10% (v/v) bovine serum, 3% BSA, or 5% Carnation nonfat milk. The antigen (rabbit IgG) was then added (50-300 ul) and incubated for 30-60 minutes, as indicated in the following Examples. After washing three times, iodinated non-immune rabbit serum (NIRS-I125) was added (50-300 ul) for the time stated (30 minutes minimum) . After a second wash, the samples were counted for gamma radiation on a 40% efficient Packard Auto-Gamma Scintillation Spectrophotometer Model 5220.
EXAMPLE 2 The Efficiency of IgG Immobilization
The efficiency of IgG immobilization on nitrocellulose disks was determined as follows. Serial dilutions of SAR were incubated with a nitrocellulose disk. The nitrocellu¬ lose filter were then washed and titrated with iodinated antisera. A plot of the amount of bound IgG, as represented by the amount of radioactivity, appears schematically in the inset to Figure 2. The competition between IgG and the larger proportion of other serum proteins for protein binding sites on nitrocellulose results in the affinity displacement (A) of IgG at high serum concentrations. As the antiserum concentration diminishes, the amount of immobilized IgG increases until the inflection point (X) is reached, where all the sample protein is absorbed equally. Diminishing concentrations of IgG beyond the inflection point are then reflected by diminishing counts of titrating antibody (B) .
This inflection point can be displaced to higher serum concentrations if desired simply by providing more nitrocel¬ lulose binding sites. Figure 2 shows the relationship between the number of nitrocellulose disks and the amount of bound radioactivity. 500 uL of sheep anti-rabbit serum was incubated for 10 minutes with 1-10 disks as shown in Figure 2, washed with Tris buffer, blocked with 1 ml of 10% bovine serum blocker for 20 minutes, washed, titrated with 1 ml of NIRS-I125 for 60 minutes, washed, and the radioactivity bound to the disk determined. At a tenfold increase in nitrocel¬ lulose surface area, the number of binding sites was no longer limiting for that concentration of sample. This illustrates that it is advantageous to use dilute sera for coating the matrix. Alternatively, purified IgG may be used to achieve high coating densities.
EXAMPLE 3 Stability of the Immobilized IgG
The stability of immobilized IgG on different immobili¬ zation matrices, with and without 20% methanol, was deter¬ mined as follows. Disks of cellulose or nylon papers were incubated with iodinated SAR in Tris-EDTA for 20 minutes, with or without 20% methanol. The disks were then washed with Tris-EDTA. and the radioactivity bound to the disks measured. The following papers were tested: 1) BioRad Zeta Probe, 2) Millipore nitrocellulose HA 0.45 uM pore, 3) Millipore mixed esters 0.22 uM pore, 4) Millipore MF 0.45 uM pore, 5) S&S Nytran 0.2 uM pore, 6) S&S 100% nitrocellulose 0.025 uM pore, 7) S&S Nytran 0.45 uM pore, 8) S&S 100% nitrocellulose, 0.2 uM pore, 9) S&S 100% nitrocellulose, 0.45 uM pore, 10) Amersham Hybond Nitrocellose, 11) Amersham Hybond nylon. The amount of bound radioactivity is depicted in Figure 3. The relative abilities of different papers to absorb iodinated SAR under the best conditions (with (+) or without (-) 20% methanol) is depicted in Figure 4. Millipore 0.45 uM pore nitrocellulose gave the best results and was chosen for all subsequent experiments. Mixed acetate paper also performed well despite reports in the literature that such papers poorly absorbed proteins (Gershoni, J.M. , et al♦ . Anal. Biochem. 131:1-15 (1983)). For S&S pure nitrocellulose paper, smaller pore sizes performed better (0.02 versus 0.45 uM) .
The effect on stability of the immobilized IgG was then examined during recycling. Nitrocellulose disks in this experiment, were recycled four times. Nitrocellulose disks containing immobilized sheep anti-rabbit IgG and titrating antibody NIRS-I125 were eluted with 2.5 M MgCl2 and the loss of antibody during the elution cycle determined. Four elutions with MgCl resulted in a 20% loss of absorbed antibody (as determined by iodinated sheep anti-rabbit serum) as. shown in Figure 5. To test the functional integrity of the SAR remaining after each cycle of the elution, the disks were incubated with 150 uL of iodinated NIRS-antigen for 60 minutes, followed by washing in milk buffer, and counting the radioactivity remaining on the disk. Background counts were determined using the counts adhering after elution of the iodinated antigen. All data as shown in Figure 5 is normali¬ zed as a percentage of the starting value. During regenera¬ tion cycles, nonspecific binding increased gradually, which indicates the absorption of label onto sites vacated by the trlσcker protein or the sheep anti-rabbit serum.
EXAMPLE 4 Optimization of Amounts of Immobilized IgG
In this example, the amount of IgG necessary to give a readable signal was .determined. Five ul aliquots of serial dilutions of SAR were spotted onto disks of nitrocellulose and dried. They were blocked for 30 minutes in 2 ml of 5% nonfat milk, washed in Tris-EDTA, and incubated with 150 ul of iodinated NIRS in 3% BSA for 60 minutes. Following thorough washing, the radioactivity bound to the disks was determined. As can be seen in Figure 6, the lowest detect¬ able amount of bound IgG under these conditions was approxi¬ mately 25 ng. A parallel series of experiments were con¬ ducted by amplifying the detection signal with iodinated SAR. Again, the lowest detection limit was. about 25 ng.
The amount of IgG bound to the disks after brief incubation with a range of serum dilutions is depicted in Figure 7. 100% efficient absorption was achieved at a titre of approximately 1:500. At lower dilutions, decreasing amounts of sample IgG were absorbed onto the matrix. The capacity of the nitrocellulose is approximately 80 ug/cm2. The area of the disk used was about 1 cm2. Thus, the amount of specific IgG is far short of saturating the disk. About 50% absorption of total sample IgG was achieved by using 1:128 dilution of serum.
EXAMPLE 5 Optimization of Incubation Time for Disk Coating
To achieve maximal immobilization of antisera, serial dilutions of SAR were incubated with nitrocellulose disks for 10 minutes or overnight. A comparison of a 10 minute incubation with an overnight incubation for a wide range of SAR dilutions is shown in Figure 8. A 10-minute incubation bound more IgG than an overnight incubation. In addition, an overnight incubation showed an inflection point. The development of the inflection point only in the longer incubation time is due to the displacement of IgG by other serum proteins, due to either mass action or affinity differences. At all dilutions of SAR, the binding of IgG was diminished with the longer incubation time. After incuba- tion, the samples were washed, blocked with 1 ml of 5% nonfat milk for 20 minutes, washed again and incubated with 450 ml of iodinated NIRS for 60 minutes in nonfat milk buffer. After thorough washing, the radioactivity bound to the disks was measured and is presented in Figure 8. The relationship of the time of incubation for shorter time periods and the radioactivity bound to the disks appears in Table 1.
TABLE 1
Radioactivity bound to disk SAR concentration Time of incubation (minutes) Undiluted 1:4 0 (blank)
1 171 ± 20 158 ± 12 523 ± 2
5 155 + 9 199 ± 16 984 ± 14
10 151 + 33 171 ± 26 738 ± 13
20 162 + 7 318 ± 159 1036 ± 136
40 126 + 4 172 ± 0 718 ± 147
130 146 + 33 215 + 57 1190 + 8
Undiluted, 1:4, and samples with no SAR were spiked with iodinated SAR, and 100 ul incubated with each disk for the time shown. After washing with. 2 ml volumes of 5% nonfat milk buffer, the counts remaining on the disks were deter¬ mined. The total counts added initially were 3610 + 596. Thus, the percentage of the total that became bound ranged from 14% at one minute to 33% at 130 minutes. The counts are expressed as mean and SD of duplicates. Maximal binding of IgG in a 100 ul sample occurred at 20 minutes at a 1:4 dilution. However, this data was not significantly different from the 10 minute incubation. Table 2 depicts the percen¬ tage of total counts bound to the blank disk for each length of time. The binding plateaus between 10-20 minutes. Adequate coating of disks was achieved using 100 ul of SAR at a dilution of 1:200 for 10 minutes.
TABLE 2
Time (minutes) % of Total Counts Bound to Blank Disk
1 14.5 ± 0.3
5 27.2 ± 2
10 20.4 ± 2
20 28.7 ± 13
40 19.9 + 2
134 32.9 + 0.6
Legend: Timecourse of SAR adsorption onto nitrocellulose disks. The data is derived from Table 1.
EXAMPLE 6 Optimization of Incubation Time With Titrating Antibody
The relationship between the time of incubation of the titrating labeled antibody (60 or 140 minutes) and the amount of bound label for various serial dilutions of NIRS appears Figure 10. The disks were coated with SAR at a 1:4 dilution (100 ul for 20 minutes) , blocked for 20 minutes in 1 ml of 5% nonfat milk buffer, and incubated with 200 ul of serial dilutions of NIRS serum overnight at 4*C. After thorough washing, the free sites were titrated with 100 ul of iodinated NIRS for the time specified. After washing, the radioactivity bound to the disk was determined.
The 140 minute incubation did increase the amount of bound label and the amplitude of the signal, although the error bars were greater. This indicated that there was an increased amount of nonspecific binding with longer incuba¬ tion times. The amplification was greatest at low concentra¬ tions of sample NIRS, where the number of free IgG binding sites was greatest. The titrating antibody may have a greater affinity for the immobilized IgG than the sample antigen.
EXAMPLE 7
Amplification by Two Iodinated Titrating IgG's
The effect of amplification of the signal was then examined. Antigen-free IgG molecules were incubated with iodinated NIRS followed by binding the remaining unbound IgG molecules with an excess of unlabeled anti-IgG molecules to provide a carpet for the subsequent binding of a second labeled anti-IgG molecule. Amplification occurs as a result of the ability of each immobilized primary antibody to bind to more than one labeled IgG molecule. This second layer of molecules allows a higher binding of a second labeled titrating antibody by virtue of mass action. Further, there is a higher probability of collision between the titrating IgG molecule and the "carpet" target IgG molecules than collision with primary immobilized antibody due to their number. Amplification resulted in an increase in the signal, especially where there was less antigen-bound IgG. Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters and concentrations and conditions without departing from the spirit and scope of the invention or any embodiment thereof. The descriptions disclosed herein refer only to a model system. Any antibody-antigen combination may be determined by one of ordinary skill in the art without undue experimentation.

Claims

WHAT IS CLAIMED IS:
1. A method for determining the presence of an analyte in a sample, comprising: a) contacting a sample suspected of containing the analyte with a solid phase support onto which an analyte- specific first antibody has been immobilized; b) incubating said sample with said support for a sufficient amount of time to allow the analyte present in the sample to bind to said first antibody; c) separating said solid phase support from the incubation mixture obtained in step b) ; d) contacting said solid phase support with a detectably labeled titrating antibody which is specific for said first antibody; e) incubating the mixture formed in step d) for a time sufficient to allow said titrating antibody to bind to said first antibody; f) separating said solid phase support from the incubation mixture obtained in step e) ; and g) detecting the analyte in the sample by measur¬ ing the amount of bound labeled antibody.
2. The method of claim 1 wherein said solid phase support is selected from the group consisting of nitro¬ cellulose, diazocellulose, microtitre plates, glass, poly¬ styrene, polypropylene, polyethylene, dextran, Sepharose, agar, starch and nylon.
3. The method of claim 1, wherein said solid phase support is selected from the group consisting of nitro¬ cellulose and diazocellulose. -27-
4. The method of claim 1 wherein said detectable la is selected from the group consisting of a radioact isotope, a dye, a fluorescent label, a fluorescence-emitt metal, a bioluminescent compound, and an enzyme.
5. The method of claim 1 wherein said antibody is the IgM, IgA, IgD, IgE or IgG immunoglobulin class.
6. The method of claim 5 wherein said antibody is the IgG immunoglobulin class.
7. The method of claim 1 wherein said analyte detected quantitatively.
8. The method of claim 1, wherein said solid pha support is recycled and said analyte and titrating antibo recovered by elution with a chaotropic salt.
9. The method of claim 8, wherein said chaotropic sa is MgCl2.
10. The method of claim 1, wherein said solid pha support contains a multiplicity of different antigen-specif first antibodies, each separately immobilized to separate defined areas and said detectably labeled titrating antibo is specific for each antigen-specific first antibody.
11. A method for determining the presence of a mult plicity of analytes in a sample, comprising: a) contacting a sample suspected of containing multiplicity of analytes with a solid support on whi different analyte-specific first antibodies have be separately immobilized to separately defined areas of said solid support. b) incubating said sample with said support for a sufficient amount of time to allow the analytes present in the sample to bind to said first antibodies. c) separating the solid phase support from the incubation mixture obtained in step b) ; d) contacting said solid support with detectably labeled titrating antibodies which are specific for said first antibodies; e) incubating the mixture formed in step d) for a time sufficient to allow said titrating antibodies to bind to said first antibodies; f) separating said solid phase support from the incubation mixture obtained in step e) ; and g) detecting the analyte in the sample by measuring "the amount of bound labeled titrating antibodies to each separately defined area.
12. A kit for the detection of an analyte in a sample comprising a carrier means being compartmentalized to receive in close confinement therein one or more container means wherein a) a first container contains a solid support containing a first antibody immobilized to said solid support wherein said first antibody are specific to an analyte; b) a second container contains washing buffers; and c) a third container contains a second antibody specific for said first first antibody.
13. A kit for the detection of a multiplicity of analytes in a sample comprising a carrier means being compartmentalized to receive in close confinement therein one or more container means wherein a) a first container contains a solid support containing a multiplicity of analyte-specific first anti¬ bodies separately immobilized to separate defined areas; b) a second container contains washing buffers; and c) a third container contains a second titrating antibody specific for each analyte-specific first antibody.
14. The kit of claim 11 or 12, wherein said titrating antibody is detectably labeled.
15. The kit of claim 13, wherein said detectable label is selected from the group consisting of radioactive labels, fluorescent labels, enzyme labels, dyes, fluorescence- emitting metal labels, and bioluminescent labels.
16. The kit of claim 11 or 12, wherein said solid support is selected from the group consisting of nitro¬ cellulose, glass, polystyrene, polypropylene, polyethylene, dextran, Sepharose, agar, starch, nylon, microtiter plates, and diazocellulose.
17. The kit of claim 11 or 12, wherein said solid phase support is nitrocellulose or diazocellulose.
EP19880905482 1987-05-14 1988-05-16 Multiple antigen immunoassay Ceased EP0362284A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4937587A 1987-05-14 1987-05-14
US49375 1987-05-14

Publications (2)

Publication Number Publication Date
EP0362284A1 true EP0362284A1 (en) 1990-04-11
EP0362284A4 EP0362284A4 (en) 1990-12-05

Family

ID=21959487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880905482 Ceased EP0362284A4 (en) 1987-05-14 1988-05-16 Multiple antigen immunoassay

Country Status (3)

Country Link
EP (1) EP0362284A4 (en)
CA (1) CA1308350C (en)
WO (1) WO1988008978A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2233450B (en) * 1989-06-24 1993-06-30 Univ Wales Medicine Detecting or quantifing multiple analytes with luminescent reagents
AU8654891A (en) * 1990-08-10 1992-03-02 Purdue Research Foundation Matrix sequential addition immunoassay
WO1993014403A1 (en) * 1992-01-06 1993-07-22 Baxter Diagnostics Inc. Multi-test immunochemical reagent and method to use same
WO1994003807A1 (en) * 1992-08-03 1994-02-17 Gec-Marconi Limited Separation method
US5573911A (en) * 1994-10-03 1996-11-12 Lifecodes Corp. Methods and materials for detecting autoimmune antibodies
GB0129776D0 (en) * 2001-12-13 2002-01-30 Sec Dep For Environment Food & Assay device and method
GB0415860D0 (en) * 2004-07-15 2004-08-18 Oxford Immunotec Ltd Solid supports

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427580A (en) * 1982-09-01 1984-01-24 Cornell Research Foundation, Inc. Method for separation and recovery of proteins and nucleic acids from nucleoproteins using water destructuring salts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380580A (en) * 1978-04-10 1983-04-19 Miles Laboratories, Inc. Heterogenous chemiluminescent specific binding assay
NZ190452A (en) * 1978-05-19 1981-04-24 Becton Dickinson Co Solid phase assay receptor contacted with analyte and then with labeled analyte
US4305924A (en) * 1979-08-08 1981-12-15 Ventrex Laboratories, Inc. Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system
US4254096A (en) * 1979-10-04 1981-03-03 Bio-Rad Laboratories, Inc. Reagent combination for solid phase immunofluorescent assay
US4514508A (en) * 1982-07-06 1985-04-30 Biond Inc. Assaying for a multiplicity of antigens or antibodies with a detection compound
US4693985A (en) * 1984-08-21 1987-09-15 Pall Corporation Methods of concentrating ligands and active membranes used therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427580A (en) * 1982-09-01 1984-01-24 Cornell Research Foundation, Inc. Method for separation and recovery of proteins and nucleic acids from nucleoproteins using water destructuring salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 70, no. 4, 1980, page 2479, abstract no. 23580, Biological Abstracts, Inc., Philadelphia, PA, US; R.Y. DODD: "Antibody to hepatitis B surface antigen: Immunochemical purification from standard immune serum globulin", & TRANSFUSION (PHILA) 20(2): 212-216, 1980 *
See also references of WO8808978A1 *

Also Published As

Publication number Publication date
CA1308350C (en) 1992-10-06
WO1988008978A1 (en) 1988-11-17
EP0362284A4 (en) 1990-12-05

Similar Documents

Publication Publication Date Title
US5149626A (en) Multiple antigen immunoassay
Yolken Enzyme-linked immunosorbent assay (ELISA): a practical tool for rapid diagnosis of viruses and other infectious agents.
Gosling A decade of development in immunoassay methodology
US4016043A (en) Enzymatic immunological method for the determination of antigens and antibodies
US4948726A (en) Enzyme immunoassay based on membrane separation of antigen-antibody complexes
US4652533A (en) Method of solid phase immunoassay incorporating a luminescent label
CA1179940A (en) Solid phase system for ligand assay
US5958790A (en) Solid phase transverse diffusion assay
US5126241A (en) Process for the determination of a specifically bindable substance
US20070224701A1 (en) Combination vertical and lateral flow immunoassay device
CA2041782A1 (en) Conjugate recovery binding assays and devices
US5389523A (en) Liposome immunoanalysis by flow injection assay
JP2642342B2 (en) Solid phase diffusion test method
EP0149602A1 (en) Immunometric assay using polyclonal and monoclonal antibodies and a kit for use therein
JP2002517728A (en) How to detect analytes
Rennard et al. Enzyme linked immunoassay (ELISA) for connective tissue proteins: type I collagen
EP0968422B1 (en) Improving performance of binding assays by use of more than one label
US5143825A (en) Stabilized substrate for use in an immunoassay
US7919331B2 (en) Chromatographic test strips for one or more analytes
EP0362284A1 (en) Multiple antigen immunoassay
USRE32696E (en) Enzymatic immunological method for determination of antigens and antibodies
US20190018005A1 (en) Tandemly repeated antibody-binding protein and its applications
WO1990015328A1 (en) Improved immunoassay
JPH08248029A (en) Competitive immunoassy using derivative of complex material under inspection
US20220196637A1 (en) Method and reagent for measuring thyroglobulin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FLEMING, NIGEL GENICA PHARMACEUTICAL CORP. NO. 2

A4 Supplementary search report drawn up and despatched

Effective date: 19901018

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19940926